The Role
OPPORTUNITY
Mammoth Biosciences is seeking a highly motivated Scientist II or Senior Scientist I to join our CMC team in a hands-on, cross-functional role that blends scientific ingenuity with operational excellence. This position is critical for developing, optimizing, scaling, and characterizing LNP-based delivery production processes for Mammoth's cutting-edge gene editing platforms. The ideal candidate will thrive at the interface of process development, analytics, and manufacturing—someone who can transition smoothly between the bench and discussions with external partners. This is a great opportunity to play a key role in advancing transformative gene editing therapies into the clinic and beyond.
KEY RESPONSIBILITIES
- Design and optimize LNP manufacturing processes by applying Quality by Design (QbD) principles and execute Design of Experiments (DoEs) to identify and control critical process parameters (CPPs)
- Optimize analytical methods such as DLS, Ribogreen, HPLC-CAD, IP-RP-HPLC, and endotoxin to identify and access critical quality attributes (CQAs)
- Interpret analytical data to assess process robustness and guide iterative development efforts
- Collaborate with internal teams to support process improvements and drive innovation
- Clearly present scientific findings and project updates in internal meetings and to external collaborators
- Drive technology transfer activities with external CDMO partners by preparing comprehensive technical documentation such as development reports, process summaries, and tech transfer packages to ensure successful external manufacturing
- Stay current with emerging trends in LNP technologies and contribute to strategic process improvements
- Track inventory, plan experiments, and contribute to an organized, quality-focused lab environment
REQUIRED QUALIFICATIONS
- Ph.D. in Chemical Engineering, Bioengineering, Pharmaceutical Sciences, Chemistry, or a related field with minimum of 3 years relevant industry experience; or M.S. with 6 years; or B.S. with 8 years
- Demonstrated expertise in LNP formulation and process development, including hands-on experience with microfluidic and high-shear mixing technologies, tangential flow filtration and dead-end filtration
- Proficiency in analytical characterization techniques for LNPs, including DLS, fluorescence-based assays and HPLC/UPLC methods (CAD, UV, IP-RP, SEC, IEX), including method development, troubleshooting, and data interpretation
- Experience with in-process and drug product stability studies
- Proven success in applying DoEs and statistical analysis tools for process optimization
- Experience supporting technology transfer of processes to external manufacturing environments, with a strong understanding of tech transfer best practices
- Demonstrated strong organizational skills
- A self-starter with demonstrated strong troubleshooting skills, capable of driving projects independently while contributing effectively in a collaborative, multidisciplinary environment
PREFERRED QUALIFICATIONS
- Knowledge of regulatory expectations for CMC development
- Familiarity with high-throughput screening methods
- Exposure to cell-based assays for LNP functional characterization
- Familiarity with data analysis tools and statistical methods such as JMP
- Experience with AAV vector process development or a strong interest and adaptability to learn viral delivery systems
BENEFITS
- Company-paid health/vision/dental benefits
- Unlimited vacation and generous sick time
- Company-sponsored meals and snacks
- Wellness, caregiver and ergonomics benefits
- 401(k) with company matching
Base Salary Range: $138,000 - $178,000 per year
Actual base salary will be determined by relevant professional experience, applicable skills, and internal equity.
COMPANY
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.
It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.
Mammoth Biosciences requires that all employees be vaccinated against COVID as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law.
Similar Jobs
Get Personalized Job Insights.
Our AI-powered fit analysis compares your resume with a job listing so you know if your skills & experience align.
Success! Refresh the page to see how your skills align with this role.
The Company
What We Do
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.
